Clin2
NCT07361302Possibly a fitRecruiting

Tenecteplase for stroke after 4.5 hours

Acute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,325 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You had an ischemic stroke (a clot blocking blood flow in the brain) more than 4.5 hours ago.
  • You were able to do most daily activities without help before the stroke (able to walk, dress, bathe alone).
  • You are not scheduled for a clot-removal procedure (thrombectomy) at the same hospital right now.
  • You do not have bleeding in the brain or a complete blockage of the main neck artery.
  • Your stroke symptoms are not too mild or too severe (score between 5 and 25 on a stroke scale).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07094763Recruiting
Tenecteplase for posterior stroke 4.5-24 hours after onset

This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.

Hefei
NCT07168278Not yet recruiting· Phase 3
Tenecteplase vs standard care for large vessel stroke 4.5-24 hours

This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.

Hefei, Anhui
NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07475949Not yet recruiting· Phase 3
Testing a clot-busting drug for wake-up strokes without advanced scans

This trial tests if the clot-busting drug tenecteplase can help people who have a stroke with an unknown start time (like waking up with symptoms) and cannot get an advanced brain scan. It aims to see if treatment within 3 hours of noticing symptoms is safe and effective.

Nanning, Guangxi
NCT07536165Not yet recruiting
Late-window IV tenecteplase for acute ischemic stroke

This registry tracks how well tenecteplase (a clot-busting medication) works when given more than 4.5 hours after a stroke starts. Researchers want to learn if treating strokes this late can still help patients recover.

Guangzhou, Guangdong
NCT06781385Enrolling by invitation· Phase 2
Tenecteplase after clot removal for severe stroke

This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.

Charlotte, North Carolina

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.